87 related articles for article (PubMed ID: 17159603)
1. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05.
Qiu Q; Domarkas J; Banerjee R; Katsoulas A; McNamee JP; Jean-Claude BJ
Anticancer Drugs; 2007 Feb; 18(2):171-7. PubMed ID: 17159603
[TBL] [Abstract][Full Text] [Related]
2. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
Matheson SL; McNamee JP; Jean-Claude BJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
Brahimi F; Matheson SL; Dudouit F; McNamee JP; Tari AM; Jean-Claude BJ
J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257
[TBL] [Abstract][Full Text] [Related]
4. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive.
Qiu Q; Domarkas J; Banerjee R; Merayo N; Brahimi F; McNamee JP; Gibbs BF; Jean-Claude BJ
Clin Cancer Res; 2007 Jan; 13(1):331-40. PubMed ID: 17200372
[TBL] [Abstract][Full Text] [Related]
5. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".
Rachid Z; Brahimi F; Katsoulas A; Teoh N; Jean-Claude BJ
J Med Chem; 2003 Sep; 46(20):4313-21. PubMed ID: 13678409
[TBL] [Abstract][Full Text] [Related]
6. "Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer.
Fang Y; Qiu Q; Domarkas J; Larroque-Lombard AL; Rao S; Rachid Z; Gibbs BF; Gao X; Jean-Claude BJ
Prostate; 2012 Sep; 72(12):1273-85. PubMed ID: 22290742
[TBL] [Abstract][Full Text] [Related]
7. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
Matheson SL; McNamee JP; Wang T; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
J Pharmacol Exp Ther; 2004 Dec; 311(3):1163-70. PubMed ID: 15358812
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.
Brahimi F; Rachid Z; McNamee JP; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
Biochem Pharmacol; 2005 Aug; 70(4):511-9. PubMed ID: 15982640
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line.
Qiu Q; Dudouit F; Banerjee R; McNamee JP; Jean-Claude BJ
Prostate; 2004 Apr; 59(1):13-21. PubMed ID: 14991862
[TBL] [Abstract][Full Text] [Related]
10. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties.
Qiu Q; Dudouit F; Matheson SL; Brahimi F; Banerjee R; McNamee JP; Jean-Claude BJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):1-10. PubMed ID: 12497200
[TBL] [Abstract][Full Text] [Related]
11. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).
Domarkas J; Dudouit F; Williams C; Qiyu Q; Banerjee R; Brahimi F; Jean-Claude BJ
J Med Chem; 2006 Jun; 49(12):3544-52. PubMed ID: 16759097
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach.
Al-Safadi S; Domarkas J; Han Y; Brahimi F; Jean-Claude BJ
Anticancer Drugs; 2012 Jun; 23(5):483-93. PubMed ID: 22421369
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept.
Banerjee R; Rachid Z; McNamee J; Jean-Claude BJ
J Med Chem; 2003 Dec; 46(25):5546-51. PubMed ID: 14640561
[TBL] [Abstract][Full Text] [Related]
14. Reduced isoflavone metabolites formed by the human gut microflora suppress growth but do not affect DNA integrity of human prostate cancer cells.
Raschke M; Wähälä K; Pool-Zobel BL
Br J Nutr; 2006 Sep; 96(3):426-34. PubMed ID: 16925846
[TBL] [Abstract][Full Text] [Related]
15. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship.
Rachid Z; Brahimi F; Qiu Q; Williams C; Hartley JM; Hartley JA; Jean-Claude BJ
J Med Chem; 2007 May; 50(11):2605-8. PubMed ID: 17472358
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and uptake of fluorescence-labeled Combi-molecules by P-glycoprotein-proficient and -deficient uterine sarcoma cells MES-SA and MES-SA/DX5.
Larroque-Lombard AL; Todorova M; Golabi N; Williams C; Jean-Claude BJ
J Med Chem; 2010 Mar; 53(5):2104-13. PubMed ID: 20151639
[TBL] [Abstract][Full Text] [Related]
17. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy.
Matheson SL; McNamee J; Jean-Claude BJ
J Pharmacol Exp Ther; 2001 Mar; 296(3):832-40. PubMed ID: 11181914
[TBL] [Abstract][Full Text] [Related]
18. The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41.
Matheson SL; Brahimi F; Jean-Claude BJ
Biochem Pharmacol; 2004 Mar; 67(6):1131-8. PubMed ID: 15006549
[TBL] [Abstract][Full Text] [Related]
19. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24.
Banerjee R; Huang Y; McNamee JP; Todorova M; Jean-Claude BJ
J Pharmacol Exp Ther; 2010 Jul; 334(1):9-20. PubMed ID: 20348204
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2.
Rachid Z; Macphee M; Williams C; Todorova M; Jean-Claude BJ
Bioorg Med Chem Lett; 2009 Sep; 19(18):5505-9. PubMed ID: 19665377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
